Amyloid-beta-targeted monoclonal antibodies probably resulted in little to no difference in cognitive function or in dementia severity.

Daiichi Sankyo has postponed its annual report by two weeks to allow for additional time to finalize the financial figures. | ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

An advantage of antibody-drug conjugates (ADCs) is that they allow targeted delivery of cytotoxic agents into tumors, thus improving the therapeutic index. Pfizer Inc. has developed a new ADC, ...

AACR 2026 saw thousands gathered in San Diego, California, where major progress in cancer research was revealed.

Antibody drug conjugates (ADCs) are advancing through clinical development with increasing complexity in both formulation and ...

On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended ...

Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective ...

Some CLDN6-negative patients responded to the therapy, suggesting it had biomarker-agnostic potential, though the study ...

SAN DIEGO -- Half of heavily pretreated patients with platinum-refractory ovarian cancer (PROC) responded to an ...

While the safety was more manageable, questions remain about whether the combination would best antibody-drug conjugate ...

SYNTHBODY(TM) introduces a new class of "smart drugs": protein therapeutics with built-in, multi-layered logic gates that actively change how they behave based on what they encounter in the body, a ...